Some Traders See Unusual Bullish Options Activity in ACADIA Pharmaceuticals Inc.

 Some Traders See Unusual Bullish Options Activity in ACADIA Pharmaceuticals Inc.

In today’s session ACADIA Pharmaceuticals Inc. (ACAD) registered an unusually high (5,149) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious ACAD increase. With 5,149 contracts traded and 91674 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: ACAD170120C00035000 closed last at: $1.4 or 16.7% up. About 631,797 shares traded hands. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 17.99% since March 31, 2016 and is downtrending. It has underperformed by 20.51% the S&P500.

Analysts await ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report earnings on November, 3. They expect $-0.60 EPS, down 53.85% or $0.21 from last year’s $-0.39 per share. After $-0.63 actual EPS reported by ACADIA Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -4.76% EPS growth.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage

Out of 5 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. $55 is the highest target while $34 is the lowest. The $47.90 average target is 113.93% above today’s ($22.39) stock price. ACADIA Pharmaceuticals has been the topic of 14 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Hold” rating given on Monday, August 10 by Vetr. The company was maintained on Friday, August 7 by Needham. On Thursday, August 27 the stock rating was upgraded by Piper Jaffray to “Neutral”. On Friday, January 22 the stock rating was upgraded by Piper Jaffray to “Overweight”. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Buy” rating given on Friday, September 4 by JP Morgan. The stock has “Outperform” rating given by Cowen & Co on Sunday, August 9. Leerink Swann downgraded the shares of ACAD in a report on Tuesday, May 3 to “Market Perform” rating. The rating was reinitiated by Roth Capital with “Neutral” on Wednesday, October 19. Leerink Swann initiated it with “Mkt Perform” rating and $34 target price in Tuesday, October 4 report. On Friday, August 7 the stock rating was downgraded by Piper Jaffray to “Neutral”.

According to Zacks Investment Research, “Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.”

Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.31, from 1.33 in 2016Q1. The ratio turned negative, as 32 funds sold all ACADIA Pharmaceuticals Inc. shares owned while 68 reduced positions. 41 funds bought stakes while 61 increased positions. They now own 104.57 million shares or 4.71% less from 109.74 million shares in 2016Q1.
Moreover, Rhenman & Partners Asset Mngmt has 0.29% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 50,000 shares. Moreover, Creative Planning has 0% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 7,652 shares. Axa owns 166,244 shares or 0.02% of their US portfolio. Wellington Grp Ltd Liability Partnership has 0% invested in the company for 110,944 shares. Blackrock Advisors Lc accumulated 0% or 49,880 shares. The New York-based Citigroup Incorporated has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). State Of Wisconsin Inv Board, a Wisconsin-based fund reported 62,040 shares. The New York-based Morgan Stanley has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Employees Retirement Association Of Colorado holds 0.01% or 22,365 shares in its portfolio. Weiss Multi reported 18,225 shares or 0.05% of all its holdings. Moreover, Pacad Invest has 0.03% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 6,086 shares. Winslow Evans & Crocker reported 4,400 shares or 0% of all its holdings. Tci Wealth Advisors owns 1,400 shares or 0.02% of their US portfolio. Nationwide Fund Advsr accumulated 27,320 shares or 0% of the stock. Cowen Gp Inc has 17,500 shares for 0.04% of their US portfolio.

Insider Transactions: Since July 11, 2016, the stock had 2 insider purchases, and 1 insider sale for $42.47 million net activity. Baity Glenn also sold $560,033 worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares. BAKER BROS. ADVISORS LP bought $43.00 million worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Wednesday, August 10. $32,970 worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares were bought by HARRIGAN EDMUND.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The company has a market cap of $2.64 billion. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. It currently has negative earnings. The Company’s lead drug candidate, NUPLAZID , is under development for the treatment of Parkinson’s disease psychosis (PDP).

ACAD Company Profile

ACADIA Pharmaceuticals Inc., incorporated on January 16, 1997, is a biopharmaceutical company. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).

Another recent and important ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) news was published by Seekingalpha.com which published an article titled: “ACADIA Pharmaceuticals Is Looking Increasingly Attractive” on October 26, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment